Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Jun;60(6):864-872.
doi: 10.1038/s41409-025-02564-8. Epub 2025 Apr 13.

Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

Affiliations
Comparative Study

Anti-T lymphocyte globulin plus posttransplant cyclophosphamide 25 mg/kg versus posttransplant cyclophosphamide 50 mg/kg in patients with acute leukemias

Abdullah Karakus et al. Bone Marrow Transplant. 2025 Jun.

Abstract

In this study, we aimed to compare the engraftment days, graft-versus-host disease (GVHD) development, relapse and overall survival rates in patients using myeloablative/reduced intensity conditioning regimens with posttransplant cyclophosphamide (PTCy) 25 mg/kg x2 with Anti-T lymphocyte Globulin (ATLG) (n = 29) and PTCy 50 mg/kg x2 doses (n = 41) in patients with acute leukemias. Matched related, matched unrelated, 1 mismatched unrelated, and haploidentical donors were selected for the patients. Platelet (median 11 vs 17 days) and neutrophil (median 14 vs 15 days) engraftment times were shorter in ATLG+ PTCy25 treated patients (both p < 0.05); veno-occlusive disease rates, graft failure and poor graft functions were similar between the two approaches (all p > 0.05); cumulative incidences of grade II-IV aGVHD at +100 days, grade III-IV aGVHD at +100 days, and grade II-IV cGVHD at 1-year were comparable between ATLG+PTCy25 and PTCy50 groups (all p > 0.05). Cumulative incidences of relapse and non-relapse mortality at 1-year were similar in two cohorts (both p > 0.05). PTCy50 was associated with a statistically significant benefit in terms of GVHD-free/relapse-free survival (GRFS) at 1-year (p = 0.03). Median GRFS was 115 (95% CI: 42-214) days and 248 (95% CI: 151-not reached) days, respectively [HR was 0.51 (0.28-0.95), p = 0.03; GRFS at 1-year was 20.7% vs 44.3%, respectively]. However, the groups were comparable in terms of PFS and OS. Median PFS was 332 days (95% CI: 182 days-not reached) for ATLG+PTCy25 group. It was not reached (95% CI: 210 days-not reached) for the patients who received PTCy50. Median OS was not reached in either ATLG+PTCy25 (95% CI: 191 days-not reached) or PTCy50 groups (Log rank = 0.42). Our study showed that lowering PTCy dose with ATLG seems to accelerate platelet and neutrophil engraftment rates; confers similar survival and relapse rates, similar acute and chronic GVHD frequency despite increased GRFS at 1-year.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Cumulative incidence of grade II-IV aGVHD at day +100.
Relapse and death were the competitive risk factors.
Fig. 2
Fig. 2. Cumulative incidence of grade III-IV aGVHD at day +100.
Relapse and death were the competitive risk factors.
Fig. 3
Fig. 3. Cumulative incidence of grade II-IV cGVHD at 1 year.
Relapse and death were the competitive risk factors.
Fig. 4
Fig. 4. Cumulative incidence of relapse at 1 year.
Death was the competitive risk factor.
Fig. 5
Fig. 5. Cumulative incidence of NRM at 1 year.
Relapse was the competitive risk factor.
Fig. 6
Fig. 6. Kaplan Meier plot for GRFS.
Follow-up was limited to 1 year.
Fig. 7
Fig. 7. Kaplan Meier plot for PFS.
Follow-up was limited to 1 year.
Fig. 8
Fig. 8. Kaplan Meier plot for OS.
Follow-up was limited to 1 year.

Similar articles

References

    1. Abedin S, Hamadani M. Contemporary updates in the prevention and treatment of graft-versus-host disease. Curr Hematol Malig Rep. 2024;19:246–55. 10.1007/s11899-024-00741-y - PubMed
    1. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18:1150–63. 10.1016/j.bbmt.2012.04.005 - PMC - PubMed
    1. Dignan FL, Clark A, Amrolia P, Cornish J, Jackson G, Mahendra P, et al. Haemato-oncology task force of British Committee for Standards in Haematology; British Society for Blood and Marrow Transplantation. Diagnosis and management of acute graft-versus-host disease. Br J Haematol. 2012;158:30–45. 10.1111/j.1365-2141.2012.09129.x - PubMed
    1. Min CK. The pathophysiology of chronic graft-versus-host disease: the unveiling of an enigma. Korean J Hematol. 2011;46:80–7. 10.5045/kjh.2011.46.2.80 - PMC - PubMed
    1. Nunes NS, Kanakry CG. Mechanisms of graft-versus-host disease prevention by post-transplantation cyclophosphamide: an evolving understanding. Front Immunol. 2019;10:2668 10.3389/fimmu.2019.02668 - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources